A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Patients with Advanced Melanoma

Trial Profile

A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Patients with Advanced Melanoma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Ipilimumab
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-006
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 16 Aug 2017 Results of the final survival analysis (Data cut off date: Dec 3, 2015) published in The Lancet.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results assessing long-term outcomes, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top